Molecular Biology Enzymes, Kits & Reagents Market to Exceed USD 63.0 Billion by 2034, with a CAGR of 13.7% and Pioneering Precision Medicine Solutions - By PMI
28 févr. 2024 17h25 HE
|
PMI
Covina, Feb. 28, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Molecular Biology Enzymes, Kits & Reagents Market size was valued at about USD 17.5 Billion in 2024 and...
Active Pharmaceutical Ingredients Market To Reach USD 346.4 Billion By 2032 at CAGR 8.7%| DataHorizzon Research
15 janv. 2024 07h30 HE
|
DataHorizzon Research
Colorado, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The Active Pharmaceutical Ingredients (API) Market size was valued at USD 151.2 Billion in 2022 and is expected to reach USD 346.4 Billion by 2032 at a...
Pharmaceutical Industry Continues to Fuel Growth of Cell-Based Assay Market – By PMI
01 nov. 2023 14h30 HE
|
PMI
Covina, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Introduction – Cell-based assays can measure a wide range of cellular activities, including cell viability, proliferation, apoptosis, and the function of...
IRBM Extends Peptide Therapeutics Collaboration with Merck & Co. Inc., Rahway NJ USA
22 juin 2023 16h30 HE
|
IRBM
ROME, June 22, 2023 (GLOBE NEWSWIRE) -- IRBM, an innovative contract research organization, today announced it has signed a new agreement with Merck & Co. Inc., Rahway NJ USA, known as MSD...
Pediatric Vaccines Market is Expected to Reach $36.4 Billion by 2031: Says AMR
18 nov. 2022 07h32 HE
|
Allied Market Research
Portland, OR, Nov. 18, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Pediatric Vaccines Market was estimated at $21.4 billion in 2021 and...
Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer
08 avr. 2021 08h00 HE
|
Immutep Limited
Fast Track designation opens the potential for expedited development and review with the US FDAFast Track was granted based on the promising data package from Immutep, including from Immutep’s Phase...
Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer
16 mars 2021 08h00 HE
|
Immutep Limited
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...
Global Diabetes Drugs Market–Analysis and Demand with Forecast Overview to 2029 - by PMI
12 janv. 2021 10h05 HE
|
PMI
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs...